

Francesc Graus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6666207/publications.pdf>

Version: 2024-02-01

141
papers

21,803
citations

20036

63
h-index

15698

129
g-index

144
all docs

144
docs citations

144
times ranked

11469
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-mediated neuropsychiatric disorders. Journal of Allergy and Clinical Immunology, 2022, 149, 37-40.	1.5	6
2	Autoimmune Cerebellar Ataxias. , 2022, , 342-367.		0
3	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
4	Autoimmune Brainstem Encephalitis. , 2022, , 368-390.		0
5	Pathogenesis and Disease Mechanisms in Neuronal Antibody-Mediated Encephalitis. , 2022, , 42-106.		1
6	Deconstructing Hashimoto Encephalopathy. , 2022, , 460-475.		0
7	CNS Syndromes at the Frontier of Autoimmune Encephalitis. , 2022, , 476-502.		0
8	Seizures and Antibodies Against Surface Antigens. , 2022, , 255-289.		0
9	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
10	Limbic Encephalitis. , 2022, , 167-190.		0
11	General Approach to Diagnosis. , 2022, , 19-41.		0
12	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.5	25
13	Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210796.	1.5	4
14	Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice. Cells, 2022, 11, 1024.	1.8	6
15	Seizure-related 6 homolog like 2 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	36
16	Incidence and Impact of COVID-19 in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
17	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, e61-e75.	1.5	54
18	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	313

#	ARTICLE	IF	CITATIONS
19	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. Annals of Neurology, 2021, 90, 101-117.	2.8	26
20	Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. Frontiers in Immunology, 2021, 12, 691536.	2.2	46
21	Thymoma and Autoimmune Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	28
22	Towards a better recognition of paraneoplastic brainstem encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1141-1141.	0.9	4
23	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology, 2021, 97, .	1.5	50
24	Autoimmune encephalitis or autoimmune psychosis?. European Neuropsychopharmacology, 2021, 50, 112-114.	0.3	9
25	Neuropathological Variability within a Spectrum of <scp>NMDAR</scp> Encephalitis. Annals of Neurology, 2021, 90, 725-737.	2.8	35
26	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. Neurology, 2021, 96, e1082-e1087.	1.5	9
27	Hashimoto encephalopathy in the 21st century. Neurology, 2020, 94, e217-e224.	1.5	92
28	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. Neurology and Therapy, 2020, 9, 281-300.	1.4	3
29	Effects of <scp>IgLON5</scp> Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Annals of Neurology, 2020, 88, 1023-1027.	2.8	61
30	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology, 2020, 95, e3012-e3025.	1.5	60
31	Clinical significance of Kelch-like protein 11 antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	54
32	Anti-IGLON5 disease. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	43
33	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	29
34	GAD antibodies in neurological disorders â€” insights and challenges. Nature Reviews Neurology, 2020, 16, 353-365.	4.9	134
35	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology, 2020, 94, e2302-e2310.	1.5	94
36	Sleep disorders in anti-NMDAR encephalitis. Neurology, 2020, 95, e671-e684.	1.5	47

#	ARTICLE	IF	CITATIONS
37	Increased CSF levels of IL-1 β , IL-6, and ACE in SARS-CoV-2-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	69
38	Pregnancy outcomes in anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	30
39	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	4.9	207
40	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e659.	3.1	30
41	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	39
42	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. <i>Lancet Neurology</i> , The, 2019, 18, 1045-1057.	4.9	497
43	Cognitive and brain structural changes in long-term oligodendroglial tumor survivors. <i>Neuro-Oncology</i> , 2019, 21, 1470-1479.	0.6	22
44	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	5.8	150
45	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 535-548.	12.5	186
46	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	44
47	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	55
48	A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. <i>Neurology</i> , 2019, 92, e244-e252.	1.5	183
49	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. <i>Journal of Neuroimmunology</i> , 2019, 326, 14-18.	1.1	12
50	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 230-234.	0.9	18
51	Antibody-Mediated Encephalitis. <i>New England Journal of Medicine</i> , 2018, 378, 840-851.	13.9	812
52	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	3.2	128
53	Encephalitis with mGluR5 antibodies. <i>Neurology</i> , 2018, 90, e1964-e1972.	1.5	139
54	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. <i>Neurology</i> , 2018, 90, e1386-e1394.	1.5	120

#	ARTICLE	IF	CITATIONS
55	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1753-1759.	1.4	71
56	Autoimmune encephalitis with GABA A receptor antibodies in a 10-year-old girl. <i>Clinical Neurology and Neurosurgery</i> , 2018, 164, 160-163.	0.6	10
57	The Sleep Disorder in Anti-IgLON5 Disease. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 41.	2.0	42
58	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	4.9	422
59	Paraneoplastic stiff person syndrome with small cell carcinoma of the bladder and anti-Ri antibodies. <i>Clinical Neurology and Neurosurgery</i> , 2018, 173, 194-195.	0.6	7
60	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	1.4	77
61	Investigations in GABA _A receptor antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1012-1020.	1.5	257
62	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. <i>Neurology</i> , 2017, 88, 1235-1242.	1.5	28
63	DPPX antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1340-1348.	1.5	170
64	Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation.. <i>Neuroradiology</i> , 2017, 59, 105-126.	1.1	18
65	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	1.0	18
66	Vanishing spinal cord after varicella-zoster virus myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e364.	3.1	1
67	Clinical manifestations of the anti-IgLON5 disease. <i>Neurology</i> , 2017, 88, 1736-1743.	1.5	300
68	Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. <i>Physiological Reviews</i> , 2017, 97, 839-887.	13.1	428
69	Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. <i>Epilepsy Research</i> , 2017, 129, 101-105.	0.8	67
70	Understanding anti-IgLON5 disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e393.	3.1	19
71	Antibody-associated CNS syndromes without signs of inflammation in the elderly. <i>Neurology</i> , 2017, 89, 1471-1475.	1.5	97
72	Neuropathological criteria of anti-IgLON5-related tauopathy. <i>Acta Neuropathologica</i> , 2016, 132, 531-543.	3.9	173

#	ARTICLE	IF	CITATIONS
73	Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. Journal of Neuroinflammation, 2016, 13, 226.	3.1	94
74	Voltage-gated potassium channel antibodies. Neurology, 2016, 86, 1657-1658.	1.5	22
75	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurology, 2016, 73, 714.	4.5	135
76	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Journal of Neurology, 2016, 263, 1349-1360.	1.8	112
77	Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodiesâ€”Reply. JAMA Neurology, 2016, 73, 891.	4.5	2
78	Human neurexin-3 antibodies associate with encephalitis and alter synapse development. Neurology, 2016, 86, 2235-2242.	1.5	116
79	Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). Journal of Neuroimmunology, 2016, 300, 15-17.	1.1	14
80	Anti-LGI1-associated cognitive impairment. Neurology, 2016, 87, 759-765.	1.5	264
81	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis â€” Authors' reply. Lancet Neurology, The, 2016, 15, 1010.	4.9	25
82	The clinical spectrum of Caspr2 antibody-associated disease. Neurology, 2016, 87, 521-528.	1.5	327
83	Ephrinâ€”2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. Annals of Neurology, 2016, 80, 388-400.	2.8	134
84	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	1.1	3
85	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
86	Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurology, 2016, 73, 417.	4.5	152
87	Pitfalls in the detection of CV2 (CRMP5) antibodies. Journal of Neuroimmunology, 2016, 290, 80-83.	1.1	27
88	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	1.4	36
89	Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. Neuro-Oncology, 2016, 18, 707-715.	0.6	35
90	Investigations on CXCL13 in Anti-N-Methyl-Aspartate Receptor Encephalitis. JAMA Neurology, 2015, 72, 180.	4.5	142

#	ARTICLE	IF	CITATIONS
91	Encephalitis and AMPA receptor antibodies. <i>Neurology</i> , 2015, 84, 2403-2412.	1.5	311
92	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2015, 72, 874.	4.5	169
93	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	5.1	340
94	IgLON5 autoimmunity and abnormal behaviours during sleep. <i>Lancet</i> , The, 2015, 385, 1590.	6.3	49
95	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. <i>Journal of the Neurological Sciences</i> , 2015, 352, 127-128.	0.3	6
96	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor β 1 Subunit in Patients With Isolated Optic Neuritis. <i>JAMA Neurology</i> , 2015, 72, 187.	4.5	119
97	Autoimmune post-herpes simplex encephalitis of adults and teenagers. <i>Neurology</i> , 2015, 85, 1736-1743.	1.5	226
98	Neuropathologic features of anti-dipeptidyl-peptidase-like protein-6 antibody encephalitis. <i>Neurology</i> , 2015, 84, 430-432.	1.5	20
99	Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e136.	3.1	62
100	Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e68.	3.1	25
101	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	1.4	241
102	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. <i>Brain</i> , 2015, 138, 94-109.	3.7	391
103	Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity. <i>PLoS ONE</i> , 2015, 10, e0121364.	1.1	127
104	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e113936.	1.1	131
105	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	4.5	59
106	Cerebellar Ataxia and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2014, 71, 1009.	4.5	154
107	Neuronal Antibodies in Creutzfeldt-Jakob Disease—Reply. <i>JAMA Neurology</i> , 2014, 71, 514.	4.5	5
108	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. <i>Lancet Neurology</i> , The, 2014, 13, 575-586.	4.9	436

#	ARTICLE	IF	CITATIONS
109	Opsoclonusâ€“myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF. <i>Journal of Neuroimmunology</i> , 2014, 272, 91-93.	1.1	26
110	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. <i>Lancet Neurology</i> , The, 2014, 13, 276-286.	4.9	525
111	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. <i>Lancet Neurology</i> , The, 2014, 13, 167-177.	4.9	758
112	Hypoglycemic seizures and epilepsy in type I diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2014, 346, 307-309.	0.3	10
113	A novel treatmentâ€“responsive encephalitis with frequent opsoclonus and teratoma. <i>Annals of Neurology</i> , 2014, 75, 435-441.	2.8	51
114	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?â€“Authors' reply. <i>Lancet Neurology</i> , The, 2014, 13, 864-865.	4.9	5
115	Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. <i>Blood</i> , 2014, 123, 3230-3238.	0.6	145
116	Encephalitis and antibodies to dipeptidylâ€“peptidaseâ€“like proteinâ€“6, a subunit of Kv4.2 potassium channels. <i>Annals of Neurology</i> , 2013, 73, 120-128.	2.8	305
117	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 157-165.	4.9	2,382
118	Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. <i>Neuro-Oncology</i> , 2013, 15, 797-805.	0.6	77
119	Paraneoplastic neuropathies. <i>Current Opinion in Neurology</i> , 2013, 26, 489-495.	1.8	48
120	Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e60438.	1.1	70
121	Paraneoplastic neurological syndromes. <i>Current Opinion in Neurology</i> , 2012, 25, 795-801.	1.8	139
122	Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. <i>Journal of Neurology</i> , 2011, 258, 2058-2068.	1.8	81
123	Does gender matter in glioblastoma?. <i>Clinical and Translational Oncology</i> , 2011, 13, 737-741.	1.2	8
124	Reply: Rapidly progressing diffuse Lewy body disease. <i>Movement Disorders</i> , 2011, 26, 2585-2585.	2.2	0
125	Antibodies and neuronal autoimmune disorders of the CNS. <i>Journal of Neurology</i> , 2010, 257, 509-517.	1.8	338
126	Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. <i>Lancet Neurology</i> , The, 2010, 9, 67-76.	4.9	805

#	ARTICLE	IF	CITATIONS
127	Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. <i>Lancet Neurology</i> , The, 2010, 9, 776-785.	4.9	947
128	Metabotropic Glutamate Receptor Type 1 Autoantibody-Associated Cerebellitis. <i>Archives of Neurology</i> , 2010, 67, 627-30.	4.9	99
129	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. <i>Annals of Neurology</i> , 2009, 65, 424-434.	2.8	712
130	Paraneoplastic neurological syndromes: diagnosis and treatment. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 82-87.	1.5	36
131	Neuro-oncology: setting new standards of management. <i>Lancet Neurology</i> , The, 2006, 5, 8-9.	4.9	1
132	The impact of the introduction of the 14-3-3 protein assay in the surveillance of sporadic Creutzfeldt-Jakob disease in Catalonia. <i>Journal of Neurology</i> , 2001, 248, 592-594.	1.8	14
133	No evidence of CNS infection with <i>Chlamydia pneumoniae</i> in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 617-618.	1.8	19
134	Epilepsia partialis continua: A new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. <i>Annals of Neurology</i> , 1999, 45, 255-258.	2.8	72
135	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. <i>Annals of Neurology</i> , 1999, 46, 774-777.	2.8	103
136	Stiff-leg syndrome: A focal form of stiff-man syndrome. <i>Annals of Neurology</i> , 1998, 43, 400-403.	2.8	62
137	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. <i>Annals of Neurology</i> , 1998, 44, 976-980.	2.8	140
138	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. <i>Cancer</i> , 1995, 75, 99-109.	2.0	159
139	Purkinje cell antibodies in a patient with cerebellar disorder. <i>Journal of Neurology</i> , 1992, 239, 237-237.	1.8	0
140	Normal proprioceptive trigeminal afferents in patients with Sjögren's syndrome and sensory neuronopathy. <i>Annals of Neurology</i> , 1990, 28, 786-790.	2.8	40
141	An antineuronal autoantibody in paraneoplastic opsoclonus. <i>Annals of Neurology</i> , 1988, 23, 528-531.	2.8	87